Announcement • Jun 30
Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2026 Results on Jul 16, 2026 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report first half, 2026 results on Jul 16, 2026 Reported Earnings • Apr 08
First quarter 2026 earnings released: EPS: CN¥0.06 (vs CN¥0.04 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.06 (up from CN¥0.04 in 1Q 2025). Revenue: CN¥219.0m (flat on 1Q 2025). Net income: CN¥36.6m (up 60% from 1Q 2025). Profit margin: 17% (up from 11% in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 1% per year. Announcement • Mar 31
Shandong Wohua Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 08, 2026 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 08, 2026 Buy Or Sell Opportunity • Mar 24
Now 20% overvalued The stock has been flat over the last 90 days, currently trading at CN¥6.20. The fair value is estimated to be CN¥5.15, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 10% over the last 3 years. Earnings per share has declined by 16%. Announcement • Jan 21
Shandong Wohua Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2025 Shandong Wohua Pharmaceutical Co., Ltd. proposed Cash dividend/10 shares (tax included) of CNY 1.46000000 for 2025 at its AGM to be held on 09 February 2026. Reported Earnings • Jan 20
Full year 2025 earnings released: EPS: CN¥0.17 (vs CN¥0.06 in FY 2024) Full year 2025 results: EPS: CN¥0.17 (up from CN¥0.06 in FY 2024). Revenue: CN¥817.0m (up 7.0% from FY 2024). Net income: CN¥95.7m (up 163% from FY 2024). Profit margin: 12% (up from 4.8% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Jan 19
Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 09, 2026 Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 09, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Weifang, Shandong China Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥7.36, the stock trades at a trailing P/E ratio of 54.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 30% over the past three years. Announcement • Dec 31
Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 20, 2026 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 20, 2026 Reported Earnings • Oct 19
Third quarter 2025 earnings released: EPS: CN¥0.031 (vs CN¥0.019 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.031 (up from CN¥0.019 in 3Q 2024). Revenue: CN¥199.3m (up 9.8% from 3Q 2024). Net income: CN¥19.3m (up 63% from 3Q 2024). Profit margin: 9.7% (up from 6.5% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Sep 30
Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 18, 2025 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 18, 2025 Reported Earnings • Jul 22
Second quarter 2025 earnings released: EPS: CN¥0.04 (vs CN¥0.002 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.04 (up from CN¥0.002 in 2Q 2024). Revenue: CN¥207.5m (up 15% from 2Q 2024). Net income: CN¥21.8m (up CN¥20.4m from 2Q 2024). Profit margin: 11% (up from 0.8% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. New Risk • Jul 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change). Announcement • Jul 02
Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Jul 22, 2025 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Jul 22, 2025 Reported Earnings • Apr 26
Full year 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.10 in FY 2023) Full year 2024 results: EPS: CN¥0.06 (down from CN¥0.10 in FY 2023). Revenue: CN¥763.8m (down 16% from FY 2023). Net income: CN¥36.4m (down 38% from FY 2023). Profit margin: 4.8% (down from 6.5% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Apr 26
Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2025 Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Weifang, Shandong China Announcement • Mar 31
Shandong Wohua Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Dec 31
Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.042 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.019 (down from CN¥0.042 in 3Q 2023). Revenue: CN¥181.5m (down 19% from 3Q 2023). Net income: CN¥11.8m (down 41% from 3Q 2023). Profit margin: 6.5% (down from 9.0% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥4.27, the stock trades at a trailing P/E ratio of 75.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 30% over the past three years. Reported Earnings • Aug 03
Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.019 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.002 (down from CN¥0.019 in 2Q 2023). Revenue: CN¥179.8m (down 30% from 2Q 2023). Net income: CN¥1.41m (down 88% from 2Q 2023). Profit margin: 0.8% (down from 4.6% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Jul 01
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to CN¥4.00. The fair value is estimated to be CN¥5.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 40%. Announcement • Jun 29
Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 03, 2024 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 03, 2024 Buy Or Sell Opportunity • Jun 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥4.00. The fair value is estimated to be CN¥5.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 40%. Buy Or Sell Opportunity • Jun 06
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to CN¥3.96. The fair value is estimated to be CN¥5.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 2.6% over the last 3 years. Earnings per share has declined by 40%. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.02 (down from CN¥0.04 in 1Q 2023). Revenue: CN¥215.3m (down 8.5% from 1Q 2023). Net income: CN¥9.67m (down 62% from 1Q 2023). Profit margin: 4.5% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥3.89, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 46% over the past three years. New Risk • Apr 14
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 250% Cash payout ratio: 114% Dividend yield: 5.4% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 250% Cash payout ratio: 114% Minor Risk Profit margins are more than 30% lower than last year (6.5% net profit margin). Reported Earnings • Apr 01
Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022) Full year 2023 results: EPS: CN¥0.10 (down from CN¥0.19 in FY 2022). Revenue: CN¥909.5m (down 10% from FY 2022). Net income: CN¥58.8m (down 45% from FY 2022). Profit margin: 6.5% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Mar 11
Now 22% overvalued Over the last 90 days, the stock has fallen 31% to CN¥4.62. The fair value is estimated to be CN¥3.80, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%. Buy Or Sell Opportunity • Feb 23
Now 23% overvalued Over the last 90 days, the stock has fallen 31% to CN¥4.68. The fair value is estimated to be CN¥3.80, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥4.44, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥4.55, the stock trades at a trailing P/E ratio of 30.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 35% over the past three years. Announcement • Dec 29
Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Mar 30, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.042. Revenue: CN¥224.1m (down 10% from 3Q 2022). Net income: CN¥20.2m (down 12% from 3Q 2022). Profit margin: 9.0% (down from 9.2% in 3Q 2022). The decrease in margin was driven by lower revenue. New Risk • Jul 30
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.8% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Jul 29
Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.019 (down from CN¥0.05 in 2Q 2022). Revenue: CN¥257.0m (up 5.2% from 2Q 2022). Net income: CN¥11.8m (down 60% from 2Q 2022). Profit margin: 4.6% (down from 12% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 21% per year. Announcement • Jul 01
Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Jul 29, 2023 Reported Earnings • Mar 23
Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021) Full year 2022 results: EPS: CN¥0.19 (down from CN¥0.28 in FY 2021). Revenue: CN¥1.01b (up 7.7% from FY 2021). Net income: CN¥107.4m (down 34% from FY 2021). Profit margin: 11% (down from 17% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 1% per year. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Shengting Li was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.04 (down from CN¥0.06 in 3Q 2021). Revenue: CN¥249.3m (up 27% from 3Q 2021). Net income: CN¥23.0m (down 34% from 3Q 2021). Profit margin: 9.2% (down from 18% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 12% per year. Reported Earnings • Jul 19
Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.05 (down from CN¥0.09 in 2Q 2021). Revenue: CN¥244.2m (down 7.0% from 2Q 2021). Net income: CN¥29.2m (down 43% from 2Q 2021). Profit margin: 12% (down from 19% in 2Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Apr 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be CN¥6.58, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.9% over the last 3 years. Earnings per share has grown by 34%. Board Change • Apr 27
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Shengting Li was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 17
First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.05 (down from CN¥0.09 in 1Q 2021). Revenue: CN¥259.4m (up 2.7% from 1Q 2021). Net income: CN¥26.9m (down 47% from 1Q 2021). Profit margin: 10% (down from 20% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • Apr 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Shengting Li was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Shengting Li was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Feb 12
Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments Shandong Wohua Pharmaceutical Co., Ltd. announced that at the Annual General Meeting held on 10 February 2022, approved election of non-independent directors, cumulative voting system applicable: Li Shengting, Chen Yong and Cui Yongmei; Election of independent directors, cumulative voting system applicable: Gao Mingqin and Yu Junli; Election of non-employee supervisors, cumulative voting system applicable: Wang Li. Reported Earnings • Jan 23
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥0.28 (down from CN¥0.31 in FY 2020). Revenue: CN¥942.7m (down 6.3% from FY 2020). Net income: CN¥163.4m (down 8.7% from FY 2020). Profit margin: 17% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥8.14, the stock trades at a trailing P/E ratio of 26.9x. Average trailing P/E is 39x in the Pharmaceuticals industry in China. Total returns to shareholders of 95% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.09 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥195.9m (down 27% from 3Q 2020). Net income: CN¥35.1m (down 30% from 3Q 2020). Profit margin: 18% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 30
Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: CN¥262.7m (down 1.1% from 2Q 2020). Net income: CN¥51.0m (up 9.4% from 2Q 2020). Profit margin: 19% (up from 18% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 07
First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥252.5m (up 16% from 1Q 2020). Net income: CN¥50.8m (up 15% from 1Q 2020). Profit margin: 20% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 09
New 90-day low: CN¥7.39 The company is down 13% from its price of CN¥8.51 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Feb 03
New 90-day low: CN¥7.55 The company is down 22% from its price of CN¥9.71 on 05 November 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Announcement • Feb 02
Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021 Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021, at 14:00 China Standard Time. Agenda: To consider the 2020 work report of the board of directors; to consider the 2020 work report of the supervisory committee; to consider the 2020 annual accounts; to consider the 2020 profit distribution plan; to consider the2020 annual report and its summary; to consider the reappointment of audit firm; to consider the loans to controlled subsidiaries; and to consider the by-election of non-employee supervisors. Reported Earnings • Jan 24
Full year 2020 earnings released: EPS CN¥0.31 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.01b (up 17% from FY 2019). Net income: CN¥178.9m (up 87% from FY 2019). Profit margin: 18% (up from 11% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jan 21
Full year 2020 earnings released: EPS CN¥0.31 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.01b (up 17% from FY 2019). Net income: CN¥178.9m (up 87% from FY 2019). Profit margin: 18% (up from 11% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥8.91, the stock is trading at a trailing P/E ratio of 27.7x, up from the previous P/E ratio of 23.5x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 19%. Is New 90 Day High Low • Dec 16
New 90-day low: CN¥8.10 The company is down 14% from its price of CN¥9.39 on 17 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day low: CN¥8.90 The company is down 16% from its price of CN¥10.64 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period. Reported Earnings • Oct 16
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥184.7m, up 256% from the prior year. Total revenue was CN¥968.8m over the last 12 months, up 13% from the prior year. Announcement • Oct 16
Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report Q3, 2020 results on Oct 16, 2020 Is New 90 Day High Low • Sep 28
New 90-day low: CN¥9.24 The company is down 17% from its price of CN¥11.10 on 30 June 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Jul 17
Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020 Shandong Wohua Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Jul 16, 2020